Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Mazouni, C; Reitsamer, R; Rimareix, F; Stranzl, H; Uzan, C; Garbay, JR; Delaloge, S; Peintinger, F; .
The positive non-sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node.
J Surg Oncol. 2012; 106(6):703-707 Doi: 10.1002/jso.23188
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Peintinger Florentia
Stranzl-Lawatsch Heidi
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Background Surgical and systemic treatment modalities for breast cancer (BC) patients with micrometastatic disease in the sentinel lymph node biopsy (SNB) are controversial. The aim of this study was to evaluate decisional factors associated with assignment of adjuvant chemotherapy (CT). Patients and Methods In a retrospective multicentric European study we evaluated cases of primary BC patients who underwent SNB. Logistic regression (LR) and recursive partitioning analyses (RPA) were performed to determine factors associated with CT. Results Of the 172 patients with micrometastatic disease, 39.5% received adjuvant CT. In the group treated with CT, patients tended to be younger (P?=?0.001), with higher grade (P?=?0.001) and HER2 positive tumors (P?=?0.006) compared to patients without CT. In multivariate LR, age (P?=?0.0027), high grading (P?=?0.01) HER2 positivity (P?=?0.03), and positive non-SN status (P?=?0.03) were significantly associated with CT. RPA demonstrated that tumor grade, and not the non-SN status, was the first split in the partition tree followed by HER2 status, and non-SN status influencing the probability for CT administration. Conclusion High tumor grade is the main decisional factor followed by HER2 positivity and then by the positive non-SN status for CT in micrometastatic disease in the SN. J. Surg. Oncol. 2012; 106:703707. (c) 2012 Wiley Periodicals, Inc.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - pathology
Chemotherapy, Adjuvant -
Female -
Humans -
Logistic Models -
Middle Aged -
Neoplasm Micrometastasis -
Receptor, erbB-2 - analysis
Retrospective Studies -
Sentinel Lymph Node Biopsy -

Find related publications in this database (Keywords)
breast cancer
micrometastasis
chemotherapy
recursive partitioning model
© Med Uni Graz Impressum